Literature DB >> 6317119

Determination of receptors that mediate opiate side effects in the mouse.

A G Hayes, M B Tyers.   

Abstract

The effects of mu and kappa-opiate receptor agonists were studied in a variety of tests in the mouse designed to correspond to clinical side-effects in man. These included sedation, decrease in pupil diameter, Straub tail, decrease in body temperature, decrease in respiratory rate and inhibition of gut propulsion. The mu-receptor agonists tested produced opiate side-effects in the mouse at doses between 2.4 and 34 times higher than their antinociceptive doses in the abdominal constriction test. Their ranked orders of potency in producing these effects were very similar to their order of antinociceptive potency. In contrast, the kappa-receptor agonists only produced opiate side-effects at doses between 29 and greater than 2500 times higher than their antinociceptive doses. There was no correlation between the potency ratios in these tests and in the abdominal constriction test. It is concluded that mu-receptor agonists may produce both their antinociceptive effects and opiate side-effects by interacting with the mu-receptor. The kappa-receptor agonists have previously been shown to produce antinociception via the kappa-receptor, but the opiate-like side-effects which appear with some of the drugs at much higher doses are probably due either to interaction with the mu-receptor or to some other non-specific action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6317119      PMCID: PMC2044905          DOI: 10.1111/j.1476-5381.1983.tb10011.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  EEG-behavioral dissociation after morphine-and cyclazocine-like drugs in the dog: further evidence for two opiate receptors.

Authors:  W B Pickworth; L G Sharpe
Journal:  Neuropharmacology       Date:  1979-07       Impact factor: 5.250

2.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

3.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Respiratory depression following single and repeated doses of pentazocine and pethidine.

Authors:  S Engineer; S Jennett
Journal:  Br J Anaesth       Date:  1972-08       Impact factor: 9.166

6.  Profiles of activity in rodents of some narcotic and narcotic antagonists drugs.

Authors:  H O Collier; C Schneider
Journal:  Nature       Date:  1969-11-08       Impact factor: 49.962

7.  Further studies on opiate receptors that mediate antinoception: tooth pulp stimulation in the dog.

Authors:  M Skingle; M B Tyers
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

  9 in total
  22 in total

1.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Shaokun Pang; Mingshe Zhu; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-09-01       Impact factor: 3.345

2.  Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists.

Authors:  A G Hayes; M J Sheehan; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

Review 3.  AH-7921: A review of previously published reports.

Authors:  Kerry Anne Rambaran; Zubair M Amin; Steven W Fleming; Liza Chacko; Saeed K Alzghari
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-06-01

4.  Antinociceptive effects of the novel opioid peptide BW443C compared with classical opiates; peripheral versus central actions.

Authors:  R L Follenfant; G W Hardy; L A Lowe; C Schneider; T W Smith
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

5.  Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man.

Authors:  C M Bradley; A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

6.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

7.  Studies on performance with aspirin and paracetamol and with the centrally acting analgesics meptazinol and pentazocine.

Authors:  C M Bradley; A N Nicholson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.].

Authors:  I Jurna; J Baldauf
Journal:  Schmerz       Date:  1993-12       Impact factor: 1.107

9.  Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Authors:  Sarah L Withey; Carol A Paronis; Jack Bergman
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

10.  A series of novel, highly potent and selective agonists for the kappa-opioid receptor.

Authors:  A G Hayes; P J Birch; N J Hayward; M J Sheehan; H Rogers; M B Tyers; D B Judd; D I Scopes; A Naylor
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.